Shire plc Study Showed VYVANSE(R) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7/1/2009
More...
|
Schering-Plough Corporation (SGP) Announces Phase II and III Data for Corifollitropin Alfa
7/1/2009
More...
|
Human Genome Sciences, Inc. (HGSI) to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
7/1/2009
More...
|
Provectus Pharmaceuticals Inc. Completes Patient Accrual in Initial Phase 2 Study of PH-10 for Atopic Dermatitis
7/1/2009
More...
|
Repros Therapeutics Inc. (RPRX) Provides Update for Proellex(R) Clinical Program
7/1/2009
More...
|
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Italian Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine
7/1/2009
More...
|
Cardioxyl Pharmaceuticals Initiates Phase I/IIa Study in Heart Failure
7/1/2009
More...
|
Saint Barnabas Medical Center is Only Hospital in New Jersey to Offer Clinical Trial for the Treatment of Recurrent Chest Wall Breast Cancer
7/1/2009
More...
|
CSL Limited (CMXHF.PK) Release: Trial Of Novel H1N1 ‘Swine’ Flu Candidate Vaccine To Take Place In Adelaide
7/1/2009
More...
|
Pharming Group (PHGUF.PK) Confirms Positive Results From Final Analysis Of Rhucin(R) Studies
7/1/2009
More...
|
deCODE genetics, Inc. (DCGN)-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia Findings Expand Knowledge of the Biology of the Disease and Provide Potential New Drug Targets
7/1/2009
More...
|
Pfizer Inc. (PFE) Updates CHANTIX(R) (varenicline) Labeling in the United States
7/1/2009
More...
|
Pfizer Inc. (PFE) Invites Public to Listen to Teleconference on Important Update Related to Chantix(R)
7/1/2009
More...
|
Important Progress for Diamyd Medical During the Third Quarter
7/1/2009
More...
|